Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of MT101-5 in Healthy Volunteers
NCT05844787Phase 1Completed
- Sponsor
- Mthera Pharma
- Start
- Jul 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MT101-5 in Parkinson's disease (PD) (7 arms), sponsored by Mthera Pharma. Primary endpoints: Incidence of Dose Limiting Toxicities, Incidence of Treatment-Emergent Adverse Events and 19 more. Started Jul 2022; status: completed.
02
Drugs
MT101-5
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05844787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05844787.